SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

10 Aug 2023 Evaluate
The revenue for the June 2023 quarter is pegged at Rs. 22531.70 millions, about 9.46% up against Rs. 20583.50 millions recorded during the year-ago period.Handsome Net Profit growth of 93.75% reported above the corresponding previous quarter figure of Rs. 2714.40 millions to Rs. 1401.00 millions.Operating profit surged to 3984.50 millions from the corresponding previous quarter of 2386.20 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 22531.70 20583.50 9.46 22531.70 20583.50 9.46 90545.50 88298.10 2.55
Other Income 647.00 553.10 16.98 647.00 553.10 16.98 2662.90 1998.90 33.22
PBIDT 3984.50 2386.20 66.98 3984.50 2386.20 66.98 16432.40 20102.50 -18.26
Interest 214.20 220.20 -2.72 214.20 220.20 -2.72 864.00 379.00 127.97
PBDT 3770.30 2166.00 74.07 3770.30 2166.00 74.07 15568.40 19723.50 -21.07
Depreciation 581.10 568.10 2.29 581.10 568.10 2.29 2298.50 2189.80 4.96
PBT 3189.20 1597.90 99.59 3189.20 1597.90 99.59 13269.90 17533.70 -24.32
TAX 474.80 196.90 141.14 474.80 196.90 141.14 1925.20 2121.20 -9.24
Deferred Tax -64.50 -78.20 -17.52 -64.50 -78.20 -17.52 -350.00 -917.00 -61.83
PAT 2714.40 1401.00 93.75 2714.40 1401.00 93.75 11344.70 15412.50 -26.39
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 17.68 11.59 52.54 17.68 11.59 52.54 18.15 22.77 -20.29

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×